A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

Inclusion Criteria: * Age\>18 years and \<70 years old (including threshold), gender not limited； * Grade II to IV gastrointestinal involvement acute graft-versus-host disease(aGVHD)； * Subjects with Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)； * Failed to second-line aGVHD treatment; * Subjects will receive NCR102 injection treatment within 3 days after enrollment; * Voluntarily sign an informed consent form. Exclusion Criteria: * Subjects have lung disease, and investigators have determined that they are not suitable for the study; * Subjects with severe hepatic vein occlusion disease or sinus vein occlusion syndrome; * Subjects with signs/symptoms of chronic GVHD; * Subjects who are clinically assessed by the investigator could not be ruled out as having diarrhea caused by cytomegalovirus (CMV) enteritis, transplant related thrombotic microvascular disease (TA-TMA), or digestive tract infection; * Eastern Cooperative Oncology Group(ECOG)\>3； * Subjects have other diseases or physiological conditions that may interfere with the evaluation results of this trial, or life-threatening complications； * Subjects had active malignant solid tumors within the past 5 years； * Subjects had a known history of severe allergies to blood products, or heterologous proteins.